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DNA Adducts as a Dosimeter for Risk
Estimation
by Steven A. Belinsky,* Catherine M. White,* Theodora R.
Devereux,* and Marshall W. Anderson*
The dose response for 06-methylguanine (O6MG) formation and cytotoxicity was determined in lung
and nasal mucosa from Fischer 344 rats during multiple dose administration ofthe tobacco-specific nitro-
samine 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). O6MG accumulated in the lung fol-
lowing treatment for 12 days with doses of NNK from 0.3 to 100 mg/kg/day. The dose response for NNK
was nonlinear; the O6MG-to-dose ratio, an index of alkylation efficiency, increased dramatically as the
dose ofcarcinogen decreased. These data suggest that low- and high-Km pathways may existforactivation
ofNNK to a methylating agent. Marked differences in O6MG concentration were observed in specific lung
cell populations. The Clara cell, one ofthe suggested progenitor cells for nitrosamine-induced neoplasia,
was found to possess the greatest concentration of O6MG. Moreover, as the dose of NNK was decreased
from 100 to 0.3 mg/kg, the alkylation efficiency in this cell population increased 38-fold. The presence of
ahigh-affinitypathway intheClaracell foractivation ofNNKmaycontributetothepotentcarcinogenicity
observed following low-dose exposure to this tobacco-specific carcinogen. The dose response for O6MG
formation differed considerably between the respiratory and olfactory mucosa from the nasal passages of
the rat. The dose response was nonlinear in respiratory mucosa but linear in olfactory mucosa. The
alkylation efficiency increased dramatically only in the respiratory mucosa as the dose of NNK was
decreased. These studies suggest that a low Km pathway for NNK activation is also present in the nose
and that this pathway is localized predominantly in the respiratory region. In contrast to alkylation data,
greater sensitivity to toxicity by NNK was observed in the olfactory region. Only mild metaplasia and a
5% incidence ofmalignant tumors were observed in the respiratory region. However, treatment with NNK
resulted in marked necrosis of the Bowman's glands and olfactory epithelium leading initially to hyper-
plasia and basal cell metaplasia and finally to a 45% incidence of malignant tumors in this area of the
nose. These data suggest that both the formation ofpromutagenic adducts and cell proliferation secondary
to toxicity are required for the induction of neoplasia by NNK within the nose.
Introduction
One of the major shortcomings in estimating carcin-
ogenic risk from long-term exposure to chemical car-
cinogens is the uncertainty of extrapolating from high
to low doses. The majority of carcinogenicity studies
encompass a dose range ofless than one order ofmag-
nitude and in some studies the dose chosen is based on
the maximumtolerable dose established from acute tox-
icity experiments. After completion of the bioassay
study, estimation of tumor incidence from low-dose
exposure may require data extrapolation over one to
two orders ofmagnitude (Fig. 1). This in turn may lead
to either over- or underestimation of the carcinogenic
potency ofmanychemicals. Recent studies (1) have sug-
gested that for chemicals with metabolites that interact
with DNA, it may be more meaningful to relate tumor
response to the target organ concentration of DNA
adducts than to the applied dose. However, this model
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FIGURE 1. Possible consequences of high-dose extrapolation from
tumor incidence data. Hypothetical data illustrating the problems
in extrapolating to low doses using tumor incidence from high-dose
exposure.
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may also be too simple to ensure accurate risk esti-
mation. Forexample, theconcentration ofDNAadducts
may vary greatly within the vast cellular heterogeneity
of tissues such as lung and kidney. There are also sev-
eral factors that may ultimately influence the initiation
of cell transformation by an environmental chemical
(Fig. 2). The electrophilic intermediate generated fol-
lowing metabolic activation of a compound can either
bind covalently to DNA, RNA, or cellular proteins, or
be removed from the cell via detoxification pathways.
Covalent binding to DNA will not always result in fix-
ation ofpromutagenic damage ifthe damaged template
is repaired before cell replication has been initiated.
Conversely, for some chemicals the efficiency for fixa-
tion of promutagenic damage may be enhanced if con-
stitutivelevels ofcellturnoverareincreased viatoxicity
or the presence of promoters such as phenobarbital.
Thus, there are many factors that must be considered
to allow more accurate estimation of the tumorigenic
potential of an environmental agent.
During the past 5 years, several laboratories (2-6)
have begun to examine the dosimetry of DNA adduct
formation and cytotoxicity during multiple-dose expo-
sure to carcinogens. Ourlaboratory has been interested
in understanding the tissue selectivity of the tobacco-
specific nitrosamine 4-(N-methyl-N-nitrosamino)-1-(3-
pyridyl)-1-butanone (NNK). In rodent carcinogenicity
studies (7) treatment with high doses ofNNK resulted
in asimilarhighincidence oflung, liver, andnasalcavity
tumors, whereas after lower doses of NNK, the prev-
alence of malignant tumors was much greater in lung
than in other target tissues. Specifically, the incidence
of malignant tumors in the nasal passages decreased
from 70% to less than 5% as the dose of NNK was
reduced from 50 to 5 mg/kg (treatment was for 20
weeks, three times a week), while the 50% incidence of
malignant neoplasiaobserved inthelungwasunaffected
after decreasing the dose of carcinogen administered.
The purpose ofthis study will be to determine whether
DNA alkylation and cytotoxicity data can explain the
differences in the dose response for induction of neo-
plasia by NNK in the nasal cavity and lung.
Cell Selective Alkylation of DNA in
the Lung
The potent carcinogenicity ofNNK may stem in part
from its metabolic activation via a-hydroxylation to a
methylating agent (8). Administration of high doses of
NNK (100 mg/kg/day) for 12 days to Fischer 344 rats
resulted in the accumulation and persistence ofthe pro-
mutagenic adduct O6MG in lung (2). The accumulation
and persistence ofthis adductcorrelated withthe deple-
tionoftherepairprotein06-methylguanine-DNAmeth-
yltransferase. These studies demonstrated that a pro-
mutagenic lesion accumulates in lung during exposure
to NNK. However, estimation ofthe carcinogenic risk
from this high-dose study (2) suffers from the problem
ofhigh- to low-dose extrapolation. Moreover, duetothe
cellular heterogeneity of the lung, the accumulation of
DNA adducts may vary greatly among specific pulmo-
nary cell populations. Therefore, the dose response for
O6MG formation in DNA from lung and specific cell
populations isolated from lung was determined during
multiple administrations of NNK.
O6MG accumulated with doses of NNK ranging from
0.1 to 100 mg/kg/day throughout the 12 days of carcin-
ogen administration (3). Aplot ofadduct concentrations
as afunction ofdose after 12 days oftreatmentrevealed
that the relationship between dose and O6MG accu-
mulation was nonlinear (Fig. 3A). The slope ofthe line
was very steep with doses of NNK from 0.1 to 3 mg/
kg, but declined markedly in the dose range of 10 to
100 mg/kg. The concentration of O6MG formed to dose
of NNK ratio, an index of efficiency of alkylation,
increased dramatically from 0.6 to 11.4 as the dose of
NNK was decreased from 100 to 0.1 mg/kg/day (Fig.
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FIGURE 2. Factors that can influence the initiation ofcell transformation. A flow diagram illustrating the complexity ofthe process ofchemically
induced cell initiation.
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FIGURE 3. Dose response (A) and efficiency of 06-methylguanine formation (B) in lung. (A) 06-methylguanine was determined in lungs from
rats treated for 12 days with 0.1, 0.3, 1, 3, 10, 30 or 100 mg/kg NNK, as described in (3). Points are means from four rats; bars, SE. (B)
Concentration of O6MG (pmole O6MG/p.mole guanine) in lungs after 12 days of treatment with NNK was divided by the dose of carcinogen
(mg/kg/day) and plotted against dose.
3B). These studies demonstrate that the efficiency for
O6MG formation from NNK is much greater after low
than high doses of carcinogens. Therefore, the extrap-
olation of carcinogenic risk from NNK using high-dose
alkylation data would greatly underestimate risk.
However, data only from the target organ may be
insufficient for accurate risk assessment. The Clara cell,
although accounting for only 1% ofthe pulmonary cells
in the lung ofthe rat, was found to possess the highest
concentration of O6MG following treatment with NNK
(Table 1). Moreover, as the dose ofNNKwas decreased
from 100 to 0.3 mg/kg, the alkylation efficiency in this
Table 1. Predominance of06-methylguanine in Clara cells
following multiple doses of NNK.a
pmole O6MG/gmole guanine
NNK treatment, Alkylation efficiency,
mg/kg/day O6MG/dose, mg/kg/day
Cell type 0.3 100 0.3 100
Whole lung 0.9 ± 0.2 43 ± 3 3.0 0.4
Alveolar small 1.5 ± 0.7 40 5.0 0.4
cells
Alveolar macro- 3.8 + 0.6* 173 ± 7* 12.7 1.7
phages
Type II cells 1.1 ± 0.2 44 ± 4 3.7 0.4
Clara cellsb 28.2 ± 1.7* 254 ± 8* 93.2 2.5
aRats were treated for 4 days with either 0.3 or 100 mg/kg NNK.
Animals were sacrificed 4 hr after treatment on day 4. Lungcells were
pooled and isolated from 6-12 rats, and DNA was isolated for deter-
mination of O6MG by competitive radioimmunoassay as described in
(3). Alkylation efficiency was determined by dividing the concentration
ofO6MG by dose of NNK. Values are means ± SE from 3 to 4 sets of
animals.
bCalculated levels of O6MG in Clara cells, excluding contamination
from other cell types.
*Significant difference (p <0.01) when compared to whole lung.
cell population increased 38-fold. This was in contrast
to the eightfold increase in alkylation efficiency
observed in lung.
The decrease in alkylation efficiency during exposure
to high doses of NNK probably cannot be explained by
cytotoxicity, since treatment of rats for 12 days with
NNK (100 mg/kg/day) caused no alterations in cell mor-
phology based on histological examination (2). Also, one
would not expect the complex kinetics of methylation
in the lung to be influenced by hepatic metabolism
because the dose response foralkylationinthe liver was
linear (S. A. Belinsky, unpublished data), indicating
that the effective dose ofNNKreachingthe lung should
be pro6portional to the injected dose. The high efficiency
for O MG formation following low-dose exposure to
NNK may stemfromthe presence ofmultiplepathways
for activation ofthis carcinogen in the lung. The metab-
olism ofNNKto amethylating agentisthoughtto occur
by cytochrome P-450-dependent a-hydroxylation (8).
Recently, several different cytochrome P-450 isozymes
have been identified in the rat lung (9). Based on the
two-component nature ofthe alkylation efficiency curve
(Fig. 3), we hypothesizethatlowand highKm pathways
exist for the activation of NNK to a methylating agent
in the lung. This hypothesis is supported by both auto-
radiographic studies and alkylation data. Autoradi-
ographic grains were more heavily concentrated over
Clara cells than over other cell types in the lung after
treatment of rats with 1 mg/kg NNK (3). In addition,
the increase in alkylation efficiency, which occurred as
the dose of NNK was decreased, was much greater in
Clara cells than in other pulmonary celi types. Taken
together, these data suggest that a lowKm pathway for
activation of this tobacco-specific carcinogen is more
-
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FIGURE 4. Dose response (A,B) and efficiency of 06-methylguanine formation (C,D) in nasal mucosa. 06-methylguanine was determined in
respiratory (A) and olfactory (B) mucosa from rats 4 hr after treatment with 0.3, 1, 3, 10, 30 and 100 mg/kg NNK as described in (10). The
concentration of O6MG (pmole/,mole guanine) in respiratory (C) and olfactory (D) mucosa 4 hr after treatment with NNK was divided by the
dose of carcinogen (mg/kg) and plotted against dose.
concentrated within the Clara cell. Thus, the presence
ofa high-affinity pathway in the Clara cell for activation
of NNK may be an important factor in the carcinogen-
icity of this tobacco-specific nitrosamine following low-
dose chronic exposure.
Cell Selectivity for DNA Alkylation
and Cytotoxicity in the Nasal
Passages
During multiple administrations of NNK (2), DNA
alkylation was also detected in the nasal passages and
liver from the Fischer rat. In fact, after 1 day oftreat-
mentwith NNK(100mg/kg), theconcentration ofO6MG
was greatest in nasal mucosa, followed by concentra-
tions ofO6MG inthe liverand lung(2). However, during
the next 5days oftreatment, alkylation ofDNAin nasal
epithelium declined to one-half the initial amount and
remained constant for the remaining 6 days of carcin-
ogen administration. The decrease in O6MG concentra-
tion appeared to be the result of cytotoxicity induced
by exposure to NNK. To better understand the rela-
tionship between DNA damage and cytotoxicity in the
induction of neoplasia in the nose by NNK, the dose
responseforthesebiologicalendpoints wasestablished.
The dose response for O6MG formation differed con-
siderably between respiratory and olfactory mucosa.
The concentration ofO MG was two tofourtimes great-
er in respiratory than olfactory mucosa after treatment
with doses of NNK ranging from 0.3 to 3.0 mg/kg and
60 to 90% higher during multiple dose administration
(10). The dose response was nonlinear in respiratory
mucosa where the slope ofthe curve was very large for
doses ofNNK ranging from 0.3 to 3.0 mg/kg, but much
smaller in the dose range of 10 to 100 mg/kg (Fig. 4A).
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In contrast, the dose response in the olfactory mucosa
did not demonstrate such a large change in slope over
the same dose range (Fig. 4B). The alkylation efficiency
increased dramatically only in the respiratory mucosa
as the dose ofNNK was decreased from 100 to 0.3 mg/
kg (Fig. 4C,D). The difference in the shape ofthe dose-
response curves for O6MG in respiratory and olfactory
mucosa may stem from the localization of metabolic
pathways for biotransformation of NNK. The amount
ofO6MG formed per unit dose ofNNK increased eight-
fold inrespiratory mucosaasthe dose ofcarcinogenwas
decreased from 100 to 0.3 mg/kg (Fig. 4). A similar
alkylation efficiency curve for O6MG has also been
observed in rat lung after treatment with NNK (Fig.
3). The factthatthe concentration ofO6MGwas greater
in respiratory than olfactory mucosa and that the effi-
ciency for alkylation increased only in respiratory
mucosa after low-dose exposure suggests that a lowKm
pathway for NNK activation is also present in the nose
and that this pathway is localized predominantly in the
respiratory region. This conclusion is supported by
autoradiographic studies that demonstrated that silver
grainsweremoreheavilyconcentrated overrespiratory
than olfactory epithelium (10) 4 hr after treatment of
rats with 1 mg/kg NNK.
Because DNA isolated from respiratory mucosa is
selectively alkylated afterlowdoses ofNNK, onewould
hypothesize that this region would also exhibit greater
sensitivity for cytotoxicity and neoplasia than the olfac-
tory mucosa following carcinogen exposure. However,
no toxicity was observed in either portion of the nasal
passages (10) with the dosing regimen that gave the
largest difference in alkylation between the tworegions
of the nose (1 mg/kg). Following exposure to higher
doses of NNK, the respiratory mucosa and underlying
glands were more resistant to toxicity and neoplasia,
exhibiting only mild metaplasia and a 5% incidence of
malignant tumors. In contrast, treatment with NNK
resulted inmarked necrosis ofthe Bowman'sglands and
olfactoryepithelium, leadinginitially tohyperplasia and
basal cell metaplasia, and finally to a 45% incidence of
malignant tumors in this area of the nose (10). Based
on autoradiography and alkylation studies, it is appar-
ent that the differential toxicity to the nasal passages
induced by NNKcannotbe attributed to eitherthe local
concentration ofDNA adducts or to the NNK itself. At
present, the mechanism for this selective toxicity is not
understood.
Theseexperiments indicatethatadductconcentration
inthenosealonemaynotbe agoodindexofcarcinogenic
riskfromNNK. Based solelyonthealkylationefficiency
curves for O6MG (Fig. 4), one would conclude that the
probability for initiation of tumorigenesis should be
muchgreaterinrespiratory thanolfactoryregions after
low-dose exposure to NNK. However, the majority of
malignant tumors induced by NNK appear to originate
from the olfactory region and occur only after chronic
treatment with high doses of NNK (16 or 50 mg/kg).
The steep dose-response curve for induction of tumors
(7), as well as the localization of lesions in the nasal
passages, can be explained by a difference in sensitivity
to cytotoxicity by NNK. Although the concentration of
O6MG was greaterinrespiratory regions afterlow-dose
exposure to NNK, no cytotoxicity was observed in
either region ofthe nose. In contrast, after exposure to
high doses of the carcinogen, adduct concentrations
were similar in both regions of the nose; however,
marked cytotoxicity was localized to the olfactory
region. Cell proliferation in the control Fischer 344 rat
is very low (0.1 to 0.2%) in both respiratory and olfac-
tory epithelium (11). Therefore, a marked increase in
cell proliferation in the olfactory region demonstrated
by severe basal cell metaplasia secondary to NNK-
induced necrosis could result in mutation at the site of
DNA adducts, clonal expansion ofinitiated cells, and a
much greater probability of cells undergoing subse-
quent critical mutations. Taken together, these data
indicate that both the formation of promutagenic
adducts and cell proliferation secondary to toxicity are
required for the induction ofneoplasia by NNK within
the nose.
The authors thank James Swenberg (Chemical Industry Institute
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